Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
59.63
+0.89 (1.52%)
At close: Oct 3, 2025, 4:00 PM EDT
59.57
-0.06 (-0.10%)
Pre-market: Oct 6, 2025, 7:18 AM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
5.39
Revenue / Employee
4,032,864 DKK
Employees
77,349
Market Cap
264.73B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Thermo Fisher Scientific | 43.21B |
NVO News
- 1 day ago - Novo Nordisk: The Bottom Is In - Seeking Alpha
- 2 days ago - Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated - Seeking Alpha
- 2 days ago - Novo plans online launch for obesity pill once approved, Bloomberg News reports - Reuters
- 3 days ago - Novo Nordisk Is Primed For A Post-Earnings Recovery (Earnings Preview) - Seeking Alpha
- 3 days ago - Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says - Barrons
- 4 days ago - Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say - Reuters
- 5 days ago - The Truth About Novo Nordisk: 4 Myths That Don't Hold Up - Seeking Alpha
- 5 days ago - LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers - Reuters